Document is current
Any future updates will be listed below
-
Authors
D’Oria, Francesco https://orcid.org/0009-0001-3446-6648
Piscazzi, Francesco https://orcid.org/0000-0001-9495-6350
Facheris, Paola https://orcid.org/0000-0002-5171-9854
Foggi, Giulio https://orcid.org/0009-0006-0527-706X
Ardigò, Marco https://orcid.org/0000-0002-5772-4937
Costanzo, Antonio https://orcid.org/0000-0001-9697-2557
Valenti, Mario https://orcid.org/0000-0001-9140-9263
- License Information
-
More Information
Article History
Received: 17 February 2026
Accepted: 18 March 2026
First Online: 9 April 2026
Declarations
:
: Paola Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, AbbVie, and Pfizer. Marco Ardigò has received consulting fees from Pierre Fabre and has participated in lectures, presentations, and advisory boards for Almirall, Kyowa Kirin, Pierre Fabre, Recordati Rare Diseases, and Cantabria Labs. Antonio Costanzo has served as an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB. Mario Valenti has served as a consultant and/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB, and Difa Cooper. Mario Valenti is a member of the Editorial Board of Dermatology and Therapy . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Francesco D’Oria, Francesco Piscazzi, and Giulio Foggi declare no conflicts of interest.
: Written informed consent was obtained from the patient for publication of clinical information and images.
